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Abstract
Background: The unparalleled success of combination antiretroviral therapy (cART) is based on the combination of three
drugs from two classes. There is insufficient evidence whether simplification to ritonavir boosted protease inhibitor (PI/r)
monotherapy in virologically suppressed HIV-infected patients is effective and safe to reduce cART side effects and costs.
Methods: We systematically searched Medline, Embase, the Cochrane Library, conference proceedings and trial registries to
identify all randomised controlled trials comparing PI/r monotherapy to cART in suppressed patients. We calculated in an
intention to treat (loss-of follow-up, discontinuation of assigned drugs equals failure) and per-protocol analysis (exclusion of
protocol violators following randomisation) and based on three different definitions for virological failure pooled risk ratios
for remaining virologically suppressed.
Findings: We identified 10 trials comparing 3 different PIs with cART based on a PI/r plus 2 reverse transcriptase inhibitors in
1189 patients. With the most conservative approach (viral load ,50 copies/ml on two consecutive measurements), the risk
ratios for viral suppression at 48 weeks of PI/r monotherapy compared to cART were in the ITT analysis 0.94 8 (95% CI 0.89 to
1.00) p=0.06; risk difference 20.06 (95%CI -0.11 to 0) p=0.05, p for heterogeneity =0.08, I
2=43.1%) and in the PP analysis
0.93 ((95%CI 0.90 to 0.97) p,0.001; risk difference 20.07 (95%CI 20.10 to 20.03) p,0.001, p for heterogeneity =0.44,
I
2=0%). Reintroduction of cART in 44 patients with virological failure led in 93% to de-novo viral suppression.
Interpretation: Virologically well suppressed HIV-infected patients have a lower chance to maintain viral suppression when
switching from cART to PI/r monotherapy. Failing patients achieve high rates of de-novo viral suppression following
reintroduction of reverse transcriptase inhibitors.
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Introduction
Modern combination antiretroviral therapy (cART) for HIV-
infected drug naı ¨ve patients consists of a combination of three
antiretroviral drugs from two classes, typically a boosted protease
inhibitor or non-nucleoside analogue (NNTRI) in combination
with two reverse transcriptase inhibitors (NRTI) [1]. Despite the
remarkable success of dual class based cART [2] and the
availability of multiple compound formulations allowing once
daily intake with low pill burden[3], the concept of treating HIV-
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maintenance therapy has attracted clinical HIV researchers over
the past years [4,5]. The rational for this therapeutic approaches is
the potential advantage of reduced adverse drug reactions, drug-
drug interactions, reduced costs and the preservation of future
treatment options in case of resistance related drug failure.
Ritonavir boosted protease inhibitors (PI/r) like, lopinavir,
atazanavir, saquinavir and darunavir are candidates for mainte-
nance mono-therapy due to their high potency and genetic barrier
for drug resistance and possibility for once daily dosing. Several
controlled and uncontrolled studies have been conducted to
examine the safety and tolerance of PI/r monotherapy for
maintenance in HIV-infected patients. Many of these studies
were small or did not use controls and evidence on the efficacy and
safety of PI/r monotherapy is therefore limited [6]. Treatment of
HIV infected patients with PI/r monotherapy for maintenance is
experimental [7] and guidelines consider PI/r monotherapy only
for selective patient groups [8]. However, more evidence of the
effectiveness, the potential risk of drug failure and PI resistance is
needed to better define the future role of PI/r mono-maintenance
therapy.
We present a systematic review and meta-analysis of random-
ized controlled trials to examine the effectiveness and safety of
antiretroviral maintenance therapy of PI/r monotherapy in
comparison with continued dual class PI/r and NRTI based
cART in virologically suppressed HIV-infected patients.
Methods
Literature search
We searched Medline, Embase, Pascal, Biological abstracts,
Web of Science and the Cochrane Central Register of Controlled
Trials from January 1996 through August 2010 for all randomized
controlled trials comparing PI-monotherapy to conventional
cART with the aid of a librarian. The following search terms
were used: (‘‘Protease inhibitors (Mesh) OR ‘‘antiretroviral
substance’’ or monotherapy (textword) OR saquinavir OR
indinavir OR lopinavir OR ritonavir OR amprenavir OR
atazanavir OR darunavir] AND (random (text word) or
randomized controlled trials (publication type)) and (limited to
humans). Two reviewers (SM and BK) independently searched
reference lists of identified articles, recently published editorials
and reviews on the topic for further eligible trials. They
additionally checked abstracts of all relevant conferences (Confer-
ence on HIV Pathogenesis, Treatment and Prevention (IAS),
International AIDS Conference, European AIDS Conference
(EACS), Conference on Retroviruses and Opportunistic Infections
(CROI), International Congress on Drug Therapy in HIV
Infection, Glasgow) and the three trial registries of planned or
ongoing clinical trials by the US Institutes of Health (http://
clinicaltrials.gov), Current Controlled Trials (http://www.controlled-
trials.com), and the WHO International Clinical Trials Registry
Platform (http://apps.who.int/trialsearch) from their inception
though August 2010 for trials that involved any of the PIs mentioned
above. We used no language restriction. Authors of included primary
trials were contacted for the identification of additional unpublished
trials and for the contribution of additional data relevant for the
purpose of this analysis.
Trial Selection
Two reviewers (SM and BK) independently checked all studies
for eligibility, disagreement was resolved by consensus. Trials were
eligible if they fulfilled the following criteria: Randomized
controlled trials comparing ritonavir boosted PI monotherapy
with cART consisting either of a PI/r or NNRTI combined with
two NRTIs, patients at randomisation had to be virologically
suppressed for at least 6 months (based on the trial specific
definition for viral suppression) and trials had to report virological
outcome data at $24 weeks. We excluded all trials that used
unboosted PIs, sequentially introduced NRTIs, or randomized
cART naı ¨ve patients to PI/r monotherapy.
Validity assessment
The quality of each included trial was independently assessed by
the two reviewers for concealment of treatment allocation,
blinding of patients, caregivers, or clinical outcome assessors,
and for the proportion of patients with complete clinical follow-up.
Treatment assignment was considered concealed if allocation was
centrally done by an independent randomisation facility and we
considered a loss of follow-up of .10% as insufficient.
Data abstraction and outcome variables
All data extraction was done independently by two reviewers.
When information from the studies was missing, incomplete or in
a format that did not allow for pooling, the authors from the
original trials were contacted for additional data. Data abstractors
were not blinded in regard to the source and authorship of
published trial data. Endpoints and adverse events were
considered irrespective of their putative relation to the treatment.
The primary endpoint for this analysis was the proportion of
patients with maintained virological suppression with failure as
defined in individual trials, HI viral loads .50 copies/ml and
.500 copies/ml in plasma on two consecutive measurements two
weeks apart at $24 weeks of follow-up. Secondary endpoints were
AIDS or death and the proportion of patients with genotypic
resistance mutations.
Quantitative data synthesis
We pooled treatment effects and calculated risk ratios and risk
differences for remaining virologically suppressed with three
different definitions for virological failure and used a random
effects model [9]. We explored heterogeneity with the Cochran Q
test and measured inconsistency (I
2 the percentage of total variance
across studies that is due to heterogeneity rather than chance) of
treatment effects across all endpoints [10,11]. We investigated the
presence of publication bias with funnel plots [12]. In the intention
to treat analysis patients with missing data, loss to follow-up or
discontinuation of assigned treatment for any reason were
considered as failure. In the per-protocol analysis we analyzed the
proportions of individuals with virological failure from all
individuals randomized to either PI/r or cART by excluding
patients with discontinuation of the assigned treatment, loss-of
follow-up or drop outs. Patients in PI/r with virological failure and
successful reintroduction of NRTIs were disregarded in our per-
protocol analysis and considered as permanent failures. We did not
a priori define a non-inferiority margin for this analysis because this
approach remains arbitrary and based on inference entirely
borrowed from external data [13,14]. We conducted a sensitivity
analysis to examine treatment effects according to quality
components of included trials (concealed treatment allocation and
sample size calculation for non-inferiority) and the type of PI. We
used Stata 10 (StataCorp, College Station/Texas) for data analysis.
Results
Trial selection process
We screened 2884 references, 2726 references could be
excluded on the basis of the title. The remaining 158 studies
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were either not randomized controlled trials or included no PI/r
monotherapy arm. We excluded all trials that compared full dose
ritonavir and saquinavir (each 400 mg bid) with a single NRTI
backbone [15–17]. We identified 17 randomized controlled trials
and excluded 7 trials for the following reasons: One trial included
naı ¨ve patients [18], one trial initiated PI/r monotherapy following
randomisation by discontinuation of the NRTI backbone [19],
three trials were conducted with unboosted PIs using mono or dual
NRTI as the comparator regimen [20–22], one trial was
conducted in viremic patients [23] and one trial reported no
virological endpoint data [24]. We identified 13 ongoing trials and
Figure 1. Flow chart for the identification of eligible trials for boosted proteinase inhibitor mono therapy in HIV infection.
doi:10.1371/journal.pone.0022003.g001
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recruit patients not virologically suppressed at study entry [25,26],
one trial does not provide virological endpoint data [27], and one
trial investigates a prepartum simplification strategy for 8 weeks in
pregnant women to prevent mother to child HIV transmission
[28]. Eight ongoing trials formally fulfil our inclusion criteria [29–
36]. Six trials use boosted lopinavir, one trial uses a mixture of PIs
[35], and one trial uses darunavir [36]. These trials will terminate
data collection with 48 week follow-up data by end of 2012 for
about 450 of 1290 anticipated study participants. Of these, three
trials recruit about 160 co-infected patients with concomitant
antiviral treatment of hepatitis C [33,34,37] and will provide data
by mid 2011. One trial was completed in 2008 but never published
[38]. Ten trials fulfilled all criteria and were included into this
analysis.
Baseline characteristics of included trials
The ten trials included a total of 1189 patients, 590 patients
treated with PI monotherapy and 599 patients with continued
cART and a total of 1094 patients for a per-protocol analysis
(Table S1). Seven trials used ritonavir boosted lopinavir [4,39–44],
two boosted darunavir[45,46] and one boosted saquinavir [47]. In
all trials the PI/r in the cART regimen was the same as in the
monotherapy arm. One trial investigated virological failure in
cerebral spinal fluid and serum and was stopped prematurely due
to increased virological failures in PI/r monotherapy recipients
[41]. For this analysis we used only failure data from the plasma.
The trials were generally small and the number of enrolled
individuals varied between 28 to 256 patients[46,47]. Six trials had
a follow up of 48 to 52 weeks [39,41,43–45,47], one trial had 72
[4,48] and three trials [40,42,46,49,50] had 96 weeks of follow-up.
In all trials patients had to be on cART for at least 6 months
with suppressed plasma viral load (i.e. ,50 copies/ml, ,80 cop-
ies/ml in one trial [42]) at randomisation. The mean age of
enrolled subjects in individual studies was about 40 years and the
percentage of enrolled males and IV drug users was between 55%
and 100% and between 29% and 46%, respectively. Four trials
described concealed allocation of patients, in the remaining trials
this information was missing. The extent of follow-up in individual
studies was good, and all trials had less than 10% patients lost to
follow-up. All trials were open interventions with no blinded
endpoint assessment. Adequate information for power calculations
was available from five trials. The relatively small number of trials
precluded a sensitive exploration of publication bias, although the
plots of standardized effect against precision for primary outcomes
did not indicate evidence for such a bias (Figures S1, S2, S3, S4,
S5, S6).
Loss of virological suppression
The studies used different definitions for virological failure. Two
trials used a cut-off ,500 copies/ml[4,40], two trials ,400 cop-
ies/ml [41,45], one trial ,200 copies/ml [43], one trial,80 co-
pies/ml [42], and four trials ,50 copies/ml [39,44,46,47] (Table
S2). Nine trials provided virological failure data with a cut-off
,50 copies/ml.
In the intention to treat analysis, the summary risk ratio at 48
weeks of follow-up of PI/r monotherapy compared to cART for
viral suppression as defined in individual trials was 0.96 ((95%CI
0.91 to 1.02) p=0.18, p for heterogeneity 0.19, I
2=27.6%; risk
difference 20.04 (95%CI 20.09 to 0.02) p=0.16, p for
heterogeneity =0.08, I
2=41.2%) (Figure 2 and Table S3). The
respective risk ratios of PI/ monotherapy compared with cART
for viral suppression with ,50 copies/ml were 0.94 [(95% CI 0.89
to 1.00) p=0.06 p for heterogeneity 0.17 I
2=30.7%; risk
difference 20.06 (95%CI -0.11 to 0) p=0.05, p for heterogeneity =
0.08, I
2=43.1%] (Figure 3 and Table S3) and for viral suppression
with ,500 copies/ml 0.98 [(95%CI 0.93 to 1.03) p.0.20, p for
heterogeneity 0.18, I
2=29.9%; risk difference 20.02 (95%CI -0.08
to 0.03) p.0.20, p for heterogeneity =0.10, I
2=39.6].
In the per protocol analysis, the summary risk ratios at 48 weeks
of follow-up of PI/r monotherapy compared to cART for viral
suppression as defined in individual trials was 0.95 ((95%CI 0.93
to 0.98) p=0.001, p for heterogeneity 0.49 I
2=0%; risk difference
20.05 (95%CI 20.08 to 20.02) p=0.001, p for heterogeneity =
0.42, I
2=2.2%) (Figure 4 and Table S3). The risk ratios of PI/
monotherapy compared with cART for viral suppression with
,50 copies/ml were 0.93 ((95% CI 0.90 to 0.97) p,0.001, p for
heterogeneity 0.49 I
2 =0%; risk difference -0.07 (95%CI 20.10 to
0.03) p,0.001, p for heterogeneity =0.44, I
2=0%) (Figure 5 and
Table S3) and for viral suppression ,500 copies/ml 0.97 ((95%CI
0.93 to 1.0) p=0.06, p for heterogeneity 0.12 I
2=39.4%; risk
difference 20.04 (95%CI 20.07 to 0) p=0.04, p for heteroge-
neity =0.09, I
2=43.8%).
In one trial with 72 weeks and three trials with 96 weeks of
follow-up the risk ratio in the intention to treat analysis of PI/r
monotherapy compared to cART for viral suppression as defined
in individual trials was 0.94 ((95%CI 0.87 to 1.03) p=0.18, p for
heterogeneity =0.87 I
2=0%; risk difference 20.5 (95%CI 20.11
to 0.02) p=0.18, p for heterogeneity 0.85, I
2=0%). In three trials
the risk ratios of viral suppression with ,50 copies/ml of Pi/r
monotherapy compared to cART were 0.95 ((95%CI 0.86 to 1.04)
p.0.20, p for heterogeneity 0.71, I
2 =0%; risk differences 20.04
(95%CI 20.12 to 0.03) p.0.20, p for heterogeneity =0.70,
I
2=0%), and for viral suppression with ,500 copies/ml 0.96
((95%CI 0.85 to 1.07) p.0.20, p for heterogeneity =0.73,
I
2=0%; risk difference 20.04, (95%CI 20.13 to 0.05) p.0.20, p
for heterogeneity =0.71, I
2=0%).
In the per-protocol analysis of three trials with 72 to 96 weeks of
follow-up the risk ratio of viral suppression as defined in individual
trials of PI/r monotherapy compared to cART was 0.98 ((95%CI
0.93 to 1.03) p.0.20, p for heterogeneity =0.52 I
2=0%; risk
difference 20.02 (95%CI 20.07 to 0.03) p.0.20, p for
heterogeneity 0.46, I
2=0%). The risk ratio of PI/r monotherapy
compared to cART for viral suppression with ,50 copies/ml were
0.92 ((95%CI 0.85 to 0.99) p=0.03. p for heterogeneity 0.63,
I
2=0%; risk difference 20.07 (95%CI 20.14 to 0.01) p=0.02, p
for heterogeneity =0.50, I
2=0%) and for viral suppression with
,500 copies/ml 0.98 ((95%CI 0.92 to 1.05) p.0.20, p for
heterogeneity 0.36, I
2=2.6%; risk difference 20.02 (95%CI 20.9
to 0.04) p.0.20, p for heterogeneity =0.29, I
2=18.9%).
In sensitivity analysis we found for all virological endpoints
similar effects sizes in subgroups of trials according to the type of
PI (lopinavir versus darunavir) and indicators of trial quality
(reporting of concealed patient allocation and power calculation
for non-inferiority) with no significant interaction in any of the
comparison pairs (data not shown).
Other results
Of 44 patients with virological failure in monotherapy groups
with reintroduction of NRTIs, 41 (93%) achieved again viral
suppression. Four trials reported PI mutations in failing patients:
There were seven patients with genotypic PI mutations with PI/r
monotherapy and three patients with cART. In two patients with
PI/r monotherapy the PI mutations had been detected already at
baseline. Following switch to another PI/r or re-introduction of
NRTIs all failing PI/r monotherapy patients with identified PI
mutations were re-suppressed. Available data precluded the formal
pooling of data on CD4 cell differences. None of the ten trials
Antiretroviral ProteAse Inhibitor Monotherapy
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22003reported a statistically significant difference in change in CD4 cells
between treatment groups. There were one death (not AIDS
related) and one AIDS case in patients with PI/r monotherapy
from one trial [40,49]. There were no differences in severe adverse
events in seven of nine trials reporting such data, but two trials
reported a higher rate of discontinuation due to adverse events in
cART arms [42,48,49].
Discussion
This meta-analysis of ten randomized controlled trials indicates
that PI/r monotherapy compared to cART with a PI/r and two
NRTIs is associated with lower virological suppression and an
increased risk of virological failure. This finding was consistent
when we used three different definitions for virological failure.
According to the virological endpoint used the absolute increase in
risk of virological failure at 48 weeks with PI/r monotherapy
compared to cART was in the intention to treat analyses between
2% and 6% and 13% at worst and in the per protocol analysis
between 5% and 6% and 10% at worst. For trials with longer
follow-up these estimates tended to be slightly worse. However,
reintroduction of NRTIs lead in 93% of patients to de-novo viral
suppression.
Our study has several strengths. It is based on a comprehensive
search and the collaborative effort of the investigators of the
primary studies to collect and present data of all included trials.
We used well defined inclusion criteria and limited our analysis to
patients on ritonavir boosted PI who were virologically well
suppressed at baseline. Primary data provided by investigators
allowed for sensitivity analysis with the use of different definitions
for virological failure and we provide relative and absolute
summary effects based on an intention to treat and per-protocol
approach.
This study presents several limitations. The methodological
quality of included trials was fair, although five trials did not report
sample size statistics to test for non-inferiority of PI/r monotherapy,
six trials did not report on concealment of treatment allocation, and
all trials used an open design with unblinded outcome assessment.
We made an effort to include all eligible trials but publication bias
cannot be ruled out and testing for publication by use of funnel plot
was uninformative due to the limited number of trials. We identified
in registries one larger trial that was never published which is of
concern. We were unable to evaluate other clinical endpoints we
had specified in the protocol as change in CD4cell count, elevations
in lipid, hepatic and renal parameters. The sample size of the
majority of included trials was small and additional trials will
contribute to increase the precision of our summary estimates. We
identified several ongoing trials that will roughly add 1300 patients
totheanalysisbutcannotbeexpected before2014.Given the recent
interest in PI/r monotherapy, nevertheless, we believe that our
findings are informative at this time.
We found heterogeneity for relative and absolute summary
estimates but the limited number of trials did not allow to further
explore differences in sensitivity analysis. Due to inconsistent
reporting we were unable to formally pool CD4 cell measure-
ments and safety data. None of the studies was powered for
clinical events and the number of AIDS defining events or death
was low.
Figure 2. Risk ratios for maintaining viral suppression, intention to treat analysis, 48 week follow-up, viral suppression as defined
in the trial.
doi:10.1371/journal.pone.0022003.g002
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experimental treatment the intention to treat analysis is conser-
vative. When non-inferiority has to be shown, this is not the case,
because any blurring of the difference between the treatment
groups will increase the chances to declare equivalence [51].
Therefore, we conducted a per protocol analysis because the
removal of uninformative patient data will increase our chances to
detect any difference between the comparison groups. Our
estimates in the intention to treat and per-protocol analyses were
very similar, although upper bounds of 95% confidence intervals
in the per-protocol analyses of all endpoints were further away
from the point estimate of no effect.
We did not define a-priori a non-inferiority margin because
subjectivity and judgement are involved in this determination.
When choosing a non-inferiority margin a conservative approach
that combines statistical reasoning and clinical judgement
reflecting uncertainties in the evidence should be taken [52].
The fixed margin method fulfils these requirements where first a
margin M1 to reflect the entire effect of the active comparator or
control regimen is calculated from past trials. A margin M2 is then
defined, the largest clinically accepted difference (degree of
inferiority) of the test drug compared to the active control [53].
The active control effect in non-inferiority trials is not measured
(there is no placebo), and therefore this effect must be assumed.
When pooling treatment effects from six randomised trials
comparing lopinavir based cART against cART regimens not
containing lopinavir - the best available evidence to suit our needs
- we may derive a relative risk margin M1 for virological
suppression (,50 copies/ml) of 0.77 (data not shown). If we were
to conclude that PI/r monotherapy would be necessary to preserve
50% of the conventional cART effect, the M2 relative risk margin
would be 0.89, corresponding to a delta of 11% for a loss of effect
to be ruled out. This estimate is conservative, because empirical
evidence indicates that investigators tend to choose for surrogate
marker endpoint trials higher non-inferiority margins [13,14].
Most antiretroviral drug trials have defined a delta of 10% to 12%
to reflect the largest difference in outcomes between treatment
arms that could reasonably be assumed to be clinically equivalent
[54].
Formally, the estimated risk differences for the ,50 copies/ml
cut-off indicated in both the intention to treat and per protocol
analysis a higher risk difference for failure in patients with PI/r
monotherapy that was of borderline significance whereas the
corresponding relative summary estimates were not all statistically
significant. The likely reasons for these discrepancies are variations
in the underlying event rates in the control groups across trials.
This meta-analysis and the included trial were formally designed
to investigate non-inferiority and not superiority and therefore
estimates for upper-bound confidence intervals should be
disregarded.
In trials with 96 weeks of follow-up viral suppression rates by any
definition tended to be lower in patients with PI/r monotherapy.
Several trials reported a higher rate of intermittent viremia in
patients with PI/r monotherapy [40,45]. No clinically relevant
differences in PI mutations were found in failing monotherapy
patients when compared to patients failing with cART and re-
intensification with two NRTIs was effective to regaining virological
suppression in the overwhelming majority of patients. These
findings are reassuring that PI/r monotherapy is a promising
approach that should be further evaluated for long-term safety.
Figure 3. Risk ratios for maintaining viral suppression, intention to treat analysis, 48 week follow-up, viral suppression ,50 copies/
ml.
doi:10.1371/journal.pone.0022003.g003
Antiretroviral ProteAse Inhibitor Monotherapy
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22003PIs have a poor central nervous system (CNS) penetration and
data from one trial [41] indicated that patients with PI/r
monotherapy have a higher rate of HIV replication in the liquor,
and in some patients HIV replication in CNS was found even
when HIV in serum was below 400 copies/ml, but this is a very
rare finding. HIV replication in the CNS with clinical CNS
symptoms in the presence of suppressed HIV in serum has been
observed by others as well [55]. Five patients with PI/r
monotherapy and confirmed HIV replication in the CNS from
two trials were found to have CNS symptoms [41,45]. In three of
these patients symptoms were quite unspecific and may have been
attributed to monotherapy in the context of the open trial design.
PI/r monotherapy may reduce long-term side effects from NRTIs
such as the risk of lipodystrophy [56,57]. It is unclear whether PI/r
monotherapy reduces the risk of bone mineral density loss and
current evidence from clinical trials whether a NRTI sparing
regimen conserves bone mineral density is conflicting [58,59].
However, according to the PI used the risk of lipid anomalies is
higher in comparison to a NNRTI based therapy. Whether PI/r
monotherapy does reduce long-term side effects is subject of
investigations of ongoing trials.
PI/r monotherapy may be associated with considerable cost
savings. In this meta-analysis we did not include a model for an
economic evaluation of the consequences of PI/r monotherapy
and costs. In an economic analysis and simulation model
Schackman et al. estimated the cost-effectiveness of a PI
simplification strategy with boosted atazanavir compared to full
cART based on efavirenz, tenofovir and emtricitabine [60]. In
their analysis the average discounted lifetime costs for the
simplification strategy was estimated to be US$ 430,200 for those
without acquired PI resistance, $383,300 for those developing PI
resistance and $ 456,700 for those on standard ART. The quality
adjusted discounted life expectancy (QALE) for patients without PI
resistance was higher (14.9 years) compared to standard care (14.7
years), however, patients with PI monotherapy and acquired PI
resistance had an estimated QALE of 14.5 years. The assumptions
for virological failure and risk of PI resistance that formed the base
in their model are in comparison to findings from this meta-
analysis overly pessimistic. Thus, the postulated gains in quality of
life and cost savings of PI monotherapy seem conservative and
would deserve confirmation in models with updated clinical data.
Whether PI monotherapy is a cost-effective strategy in resource
limited settings is unknown. Further economic studies evaluating
in particular lopinavir in resource limiting settings are needed [61].
Our findings are informative for clinicians who wish to
individualize antiretroviral therapy for HIV-infected patients with
different preferences. Virologically well suppressed patients with
excellent adherence may opt for PI/r monotherapy if they put a
high value on avoiding long-term complications from their current
NRTI backbone. The absolute increase in risk of virological failure
at one year with PI/r monotherapy is roughly 10% to 13% at
worst, with a very high chance of virological control when NRTIs
are reintroduced in case of failure. PI monotherapy is not an
option for clinicians and patients who do not want to accept this
risk. Clinicians may also be hesitant and await the results from
long-term follow-up data and more safety data in regard to HIV
replication in the CNS before offering PI/r monotherapy for
maintenance to their patients. When costs savings for antiretro-
Figure 4. Risk ratios for maintaining viral suppression, per protocol analysis, 48 week follow-up, viral suppression as defined in the
trial.
doi:10.1371/journal.pone.0022003.g004
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